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Dr. Mark Green supported the development of noveltaxanes and antimicrotubule agents during the lively
debate session. He argued that a good “theory” of business in
the pharmaceutical industry is to generate compounds that
can improve ease, safety of administration, and efficacy of
extant drugs, as exemplified by the experience with pacli-
taxel. Because paclitaxel is poorly soluble in water, it was
developed for clinical use based on Cremophor EL/ethanol as
a delivery agent (Taxol).1 Cremophor has known associated
biologic effects such as hypersensitivity reactions and neuro-
toxicity, which can significantly exacerbate innate taxane
toxicities.2 Moreover, micellar entrapment of paclitaxel by
cremophor in the plasma compartment results in nonlinear
pharmacokinetics and inhibition of intracellular transport of
paclitaxel.3,4
Nanoparticle albumin-bound (nab) technology enables
the delivery of insoluble drug without the need for a solvent,
and thus, nab-paclitaxel (ABI-007, Abraxane) can circumvent
the disadvantages of Cremophor. This is in fact borne out in
a phase III study in women with metastatic breast cancer
where Abraxane produced a higher overall response rate and
survival benefit. Even though Abraxane was delivered at a
50% higher dose of the active agent paclitaxel compared with
standard Taxol, it was generally significantly less toxic, with
shorter administration time and no hypersensitivity reactions
observed despite the absence of premedication.5
In NSCLC, a number of promising phase I/II studies of
carboplatin in combination with Abraxane demonstrated an-
titumor activity comparable with carboplatin and standard
Taxol but with less toxicity, particularly with Abraxane 100
mg/m2 weekly regimen.6 This led to the design of a phase III
study comparing carboplatin area under the curve 6/Abraxane
100 mg/m2 weekly versus carboplatin area under the curve
6/Taxol 200 mg/m2 once every 21 days as first-line therapy in
a one-to-one ratio among patients with advanced NSCLC.
This study (NCT00540514) completed enrollment of 1052
patients in July 2009 at more than 100 sites globally and met
its primary end point of disease response, which will lay the
groundwork for its application for registrational approval in
this patient population.7
Eribulin mesylate (E789) is a synthetic halichondrin B
analog that is a nontaxane inhibitor of microtubule polymer-
ization with no effect on depolymerization dynamics. In
contrast to Taxol, it has a short infusion course (2–5 minutes
on a day 1, 8 schedule every 3 weeks) and does not require
prophylactic premedication against hypersensitivity reac-
tions. In heavily pretreated patients with metastatic breast
cancer, the tumor response seen and notable absence of
severe neuropathy8 were sufficiently encouraging to lead to
two randomized phase III studies comparing eribulin against
either capecitabine (NCT00337103) or chemotherapy agent
of the treating physician’s choice (EMBRACE study;
NCT00388726), which have completed enrollment. A phase
II trial of eribulin was also conducted in 41 patients with
NSCLC who were previously treated with taxanes. Eligible
patients were classified by taxane sensitivity based on disease
progression occurring more than 90 days (TS sensitive);
during therapy or less than 90 days after taxane therapy (TR
resistant). There were three (15%) objective responses in 20
TS patients with median progression-free survival (PFS) of
6.3 months. Treatment was well tolerated, and enrollment is
continuing on a two-stage design.9
The discussion on epothilones started with an overview
of microtubule structure and function. Microtubules comprise
- and  tubulin heterodimers, which then polymerize and
assemble in sheets to form microtubules. There are six -tu-
bulin and seven -tubulin isotypes the combination of which
differ among various tissues and cell types.10 -tubulin is
essential for maintaining microtubular dynamic instability
and is the binding site of multiple microtubule-targeting
agents. Of particular interest is the III tubulin isoform,
which is overexpressed in various tumor types and has been
correlated with poor prognosis.11 Its expression is up-regu-
lated as a survival mechanism under various stress conditions
such as hypoxia, hypoglycemia, or exposure to cytotoxic
agents.12 Silencing of its expression can induce sensitivity not
only to taxanes and vinca alkaloids but also multiple other
chemotherapy agents such as cisplatin, doxorubicin, and
etoposide.13 III tubulin is highly expressed in small cell,
large cell neuroendocrine carcinoma, and approximately 40%
of NSCLC, particularly adenocarcinomas.14
Ixabepilone is a semisynthetic analog of epothilone B,
which shares a common pharmacophore with taxanes.15 It
binds to a different site of the tubulin molecule, which may
explain its lack of complete cross-resistance with other tubu-
lin-binding agents.12 It is an inhibitor of multiple -tubulin
isoforms and has demonstrable preclinical activity against
III tubulin-overexpressing lung cancer models that are re-
sistant to taxanes and vinca alkaloids.16 It showed promising
activity as a second-line agent in a phase II study of patients
with recurrent or metastatic NSCLC after failure of platinum-
based regimen, approximately half of whom had been previ-
ously treated with a taxane.17 An international randomized
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phase II trial comparing carboplatin/paclitaxel versus carbo-
platin/ixabepilone as first-line therapy for advanced NSCLC
is currently ongoing, with stratification according to III
tubulin expression. Primary end point is PFS in the subgroup
of patients with tumors that overexpress III tubulin as
determined by immunohistochemistry (NCT0000723957).
Dr. Chandra Belani riposted by reminding the audience
of the dismal fate of oral taxanes and other taxane formula-
tions (e.g., poliglumex). He questioned if any of the novel
taxanes are truly better in terms efficacy, toxicity, and cost-
effectiveness, countering that the improved primary end point
of objective response rate seen in the phase III study with
carboplatin/weekly Abraxane is irrelevant without an im-
provement in PFS and OS end points and thus perhaps will
not be sufficient to merit FDA approval. In the case of
eribulin, he emphasized that there were no responses seen in
the 21 TR patients, and median PFS in this population was
only 1.2 months.9 He summarized a published report of the
typical course of patients experiencing sensory neuropathy
from ixabepilone,17 then rhetorically asked whether the de-
scription sounds better than the experience with standard
paclitaxel. Moreover, from a cost-perspective, Taxol and
docetaxel are relatively cheap compared with any of the novel
taxanes. He presented cost estimates, using BSA assumption
of 1.7 mg/m2, of each agent per dose: Taxol 200 mg/m2 was
$1980 in contrast to Abraxane at $4919 (260 mg/m2 dose)
and Ixabepilone at $3340 (32 mg/m2). Finally, he concluded
that the FDA-approved pemetrexed-based platinum combina-
tions have demonstrated efficacy and improved tolerability
profiles in the nonsquamous subset of patients with
NSCLC.18,19 This raises the efficacy and tolerability bench-
mark for this patient population which will be difficult to
surpass.
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